Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

计划入组 1,180 人 · 首次发布于 2025 年 1 月 3 日

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

计划入组 701 人 · 首次发布于 2022 年 8 月 16 日

DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone

计划入组 31 人 · 首次发布于 2020 年 4 月 24 日

2-mercaptobenzothiazole

C₇H₅NS₂

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Gedatolisib Shows Promising 77-Month Overall Survival in Advanced Breast Cancer Phase 1b Trial

Celcuity Secures $500 Million Credit Facility Following Positive Phase 3 Data for Gedatolisib in Advanced Breast Cancer

Celcuity Secures Patent Extension for Gedatolisib Through 2042, Strengthening Breast Cancer Drug Portfolio